menu search

OPNT / Why Is Opiant Pharma (OPNT) Stock Up 116% Today?

Why Is Opiant Pharma (OPNT) Stock Up 116% Today?
Opiant Pharmaceuticals (NASDAQ: OPNT ) stock is rocketing higher on Monday following news that Indivior is acquiring the Narcan maker! Indivior is offering to acquire shares of OPNT stock for $28 each. Read More
Posted: Nov 14 2022, 10:58
Author Name: InvestorPlace
Views: 102177

OPNT News  

What's The Opiant CVR Worth?

By Seeking Alpha
February 11, 2023

What's The Opiant CVR Worth?

Opiant appears on track to be acquired for $20/share and offers various Contingent Value Rights (CVRs) linked to a potential drug launch. The drug hel more_horizontal

Opiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown In

By Seeking Alpha
January 13, 2023

Opiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown In

I love to get a CVR during a takeover process. This happens a lot when pharma or biotech companies with important unapproved assets get bought. more_horizontal

Why Is Opiant Pharma (OPNT) Stock Up 116% Today?

By InvestorPlace
November 14, 2022

Why Is Opiant Pharma (OPNT) Stock Up 116% Today?

Opiant Pharmaceuticals (NASDAQ: OPNT ) stock is rocketing higher on Monday following news that Indivior is acquiring the Narcan maker! Indivior is off more_horizontal

Opiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q1 2022 Results - Earnings Call Transcript

By Seeking Alpha
May 14, 2022

Opiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q1 2022 Results - Earnings Call Transcript

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT ) Q1 2022 Results Conference Call May 10, 2022 4:30 PM ET Company Participants Ben Atkins - Vice President, more_horizontal

Why Opiant Pharmaceuticals Shares Are Soaring Today

By Benzinga
April 28, 2022

Why Opiant Pharmaceuticals Shares Are Soaring Today

Opiant Pharmaceuticals Inc (NASDAQ: OPNT) announced topline results from a pharmacodynamic (PD) study for OPNT003, nasal nalmefene for opioid overd more_horizontal

Under BARDA Contract, Opiant Pharma Secures Additional Funding Of $2M For Opioid Overdose Program

By Benzinga
January 25, 2022

Under BARDA Contract, Opiant Pharma Secures Additional Funding Of $2M For Opioid Overdose Program

The Biomedical Advanced Research and Development Authority (BARDA) will provide additional funding of up to $2.2 million to support Opiant Pharmace more_horizontal

Under BARDA Contract, Opiant Pharma Secures Additional Funding Of $2M For Opioid Overdose Program

By Benzinga
January 25, 2022

Under BARDA Contract, Opiant Pharma Secures Additional Funding Of $2M For Opioid Overdose Program

The Biomedical Advanced Research and Development Authority (BARDA) will provide additional funding of up to $2.2 million to support Opiant Pharmace more_horizontal

Under BARDA Contract, Opiant Pharma Secures Additional Funding Of $2M For Opioid Overdose Program

By Benzinga
January 25, 2022

Under BARDA Contract, Opiant Pharma Secures Additional Funding Of $2M For Opioid Overdose Program

The Biomedical Advanced Research and Development Authority (BARDA) will provide additional funding of up to $2.2 million to support Opiant Pharmace more_horizontal


Search within

Pages Search Results: